A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Latest Information Update: 03 May 2024
At a glance
- Drugs Tazemetostat (Primary)
- Indications Adenocarcinoma; Chondrosarcoma; Chordoma; Peripheral nervous system neoplasms; Renal cell carcinoma; Rhabdoid tumour; Sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Sponsors Epizyme
- 26 Apr 2024 Status changed from active, no longer recruiting to completed.
- 31 Dec 2023 This trial has been completed in France,according to European Clinical Trials Database record
- 21 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Jun 2024.